1,014
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Comparison of resumption of ovulation after cessation of oral contraceptives and medroxyprogesterone acetate in women with polycystic ovary syndrome

, , &
Article: 2309349 | Received 18 Sep 2023, Accepted 17 Jan 2024, Published online: 02 Feb 2024

References

  • Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):1–7. doi:10.1210/jc.2003-032046.
  • Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12):1223–1236. doi:10.1056/NEJMra041536.
  • Lizneva D, Suturina L, Walker W, et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6–15. doi:10.1016/j.fertnstert.2016.05.003.
  • Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–4592. doi:10.1210/jc.2013-2350.
  • Chang RJ. The reproductive phenotype in polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab. 2007;3(10):688–695. doi:10.1038/ncpendmet0637.
  • Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet. 2003;361(9371):1810–1812. doi:10.1016/S0140-6736(03)13409-5.
  • Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8(1):41. doi:10.1186/1741-7015-8-41.
  • Balen AH, Conway GS, Kaltsas G, et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod. 1995;10(8):2107–2111. doi:10.1093/oxfordjournals.humrep.a136243.
  • Tabassum F, Jyoti C, Sinha HH, et al. Impact of polycystic ovary syndrome on quality of life of women in correlation to age, basal metabolic index, education and marriage. PLOS One. 2021;16(3):e0247486. doi:10.1371/journal.pone.0247486.
  • Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110(3):364–379. doi:10.1016/j.fertnstert.2018.05.004.
  • Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS consensus workshop group. Fertil Steril. 2012;97(1):28–38 e25. doi:10.1016/j.fertnstert.2011.09.024.
  • Conway G, Dewailly D, Diamanti-Kandarakis E, et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014;171(4):1–29.
  • Taylor HS, Pal L, Sell E. Speroff’s clinical gynecologic endocrinology and infertility. 9th ed. Philadelphia: Wolters Kluwer; 2019.
  • Hickey M, Higham JM, Fraser I. Progestogens with or without oestrogen for irregular uterine bleeding associated with anovulation. Cochrane Database Syst Rev. 2012;2012(9):CD001895. doi:10.1002/14651858.CD001895.pub3.
  • Han SJ, Kim H, Hong YS, et al. Prediction model of persistent ovulatory dysfunction in korean women with polycystic ovary syndrome. J Obstet Gynaecol Res. 2022;48(7):1795–1805. doi:10.1111/jog.15288.
  • Homburg R. Androgen circle of polycystic ovary syndrome. Hum Reprod. 2009;24(7):1548–1555. doi:10.1093/humrep/dep049.
  • Zimmerman Y, Eijkemans MJ, Coelingh Bennink HJ, et al. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(1):76–105. doi:10.1093/humupd/dmt038.
  • Ozdemir S, Görkemli H, Gezginç K, et al. Clinical and metabolic effects of medroxyprogesterone acetate and ethinyl estradiol plus drospirenone in women with polycystic ovary syndrome. Int J Gynaecol Obstet. 2008;103(1):44–49. doi:10.1016/j.ijgo.2008.05.017.
  • Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–47. doi:10.1093/humrep/deh098.
  • Faul F, Erdfelder E, Buchner A, et al. Statistical power analyses using G* power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149–1160. doi:10.3758/BRM.41.4.1149.
  • Kim JJ, Chae SJ, Choi YM, et al. Assessment of hirsutism among Korean women: results of a randomly selected sample of women seeking pre-employment physical check-up. Hum Reprod. 2011;26(1):214–220. doi:10.1093/humrep/deq303.
  • Balen AH, Laven JS, Tan SL, et al. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update. 2003;9(6):505–514. doi:10.1093/humupd/dmg044.
  • Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666–3672. doi:10.1210/jcem.84.10.6079.
  • Imai K, Ratkovic M. Covariate balancing propensity score. J Royal Statist Soc Series B. 2014;76(1):243–263. doi:10.1111/rssb.12027.
  • Rosenbaum PR. Model-based direct adjustment. J Am Stat Assoc. 1987;82(398):387–394. doi:10.1080/01621459.1987.10478441.
  • Jann B. KMATCH: stata module module for multivariate-distance and propensity-score matching, including entropy balancing, inverse probability weighting, (coarsened) exact matching, and regression adjustment, Statistical Software Components S458346: Boston College Department of Economics; 2017 [cited 2021 July 12]. Available from: https://ideas.repec.org/c/boc/bocode/s458346.html.
  • Munro MG, Mainor N, Basu R, et al. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial. Obstet Gynecol. 2006;108(4):924–929. doi:10.1097/01.AOG.0000238343.62063.22.
  • Trimble CL, Method M, Leitao M, et al. Management of endometrial precancers. Obstet Gynecol. 2012;120(5):1160–1175. doi:10.1097/aog.0b013e31826bb121.
  • World Health Organization. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: 2015. Available from: https://www.who.int/publications/i/item/9789241549158.
  • Najafi-Sharjabad F, Zainiyah Syed Yahya S, Abdul Rahman H, et al. Barriers of modern contraceptive practices among Asian women: a mini literature review. Glob J Health Sci. 2013;5(5):181–192.
  • Park H, Kim K. Trends and factors associated with oral contraceptive use among Korean women. Healthcare. 2021;9(10):1386. doi:10.3390/healthcare9101386.
  • Petsos P, Ratcliffe WA, Anderson DC. Effects of medroxyprogesterone acetate in women with polycystic ovary syndrome. Clin Endocrinol. 1986;25(6):651–660. doi:10.1111/j.1365-2265.1986.tb03620.x.
  • Anttila L, Koskinen P, Kaihola HL, et al. Serum androgen and gonadotropin levels decline after progestogen-induced withdrawal bleeding in oligomenorrheic women with or without polycystic ovaries. Fertil Steril. 1992;58(4):697–702. doi:10.1016/s0015-0282(16)55314-x.
  • Fiad TM, Cunningham SK, McKenna TJ. Role of progesterone deficiency in the development of luteinizing hormone and androgen abnormalities in polycystic ovary syndrome. Eur J Endocrinol. 1996;135(3):335–339. doi:10.1530/eje.0.1350335.
  • Homburg R, Weissglas L, Goldman J. Improved treatment for anovulation in polycystic ovarian disease utilizing the effect of progesterone on the inappropriate gonadotrophin release and clomiphene response. Hum Reprod. 1988;3(3):285–288. doi:10.1093/oxfordjournals.humrep.a136697.
  • Soules MR, Steiner RA, Clifton DK, et al. Progesterone modulation of pulsatile luteinizing hormone secretion in normal women. J Clin Endocrinol Metab. 1984;58(2):378–383. doi:10.1210/jcem-58-2-378.
  • Wiegratz I, Kutschera E, Lee JH, et al. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception. 2003;67(1):25–32. doi:10.1016/s0010-7824(02)00436-5.
  • van der Vange N, Blankenstein MA, Kloosterboer HJ, et al. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception. 1990;41(4):345–352. doi:10.1016/0010-7824(90)90034-s.
  • Coenen CM, Thomas CM, Borm GF, et al. Changes in androgens during treatment with four low-dose contraceptives. Contraception. 1996;53(3):171–176. doi:10.1016/0010-7824(96)00006-6.
  • Wortsman J, Singh KB, Murphy J. Evidence for the hypothalamic origin of the polycystic ovary syndrome. Obstet Gynecol. 1981;58(2):137–141.
  • Anttila L, Koskinen P, Erkkola R, et al. Serum testosterone, androstenedione and luteinizing hormone levels after short-term medroxyprogesterone acetate treatment in women with polycystic ovarian disease. Acta Obstet Gynecol Scand. 1994;73(8):634–636. doi:10.3109/00016349409013457.
  • Bagis T, Gokcel A, Zeyneloglu HB, et al. The effects of short-term medroxyprogesterone acetate and micronized progesterone on glucose metabolism and lipid profiles in patients with polycystic ovary syndrome: a prospective randomized study. J Clin Endocrinol Metab. 2002;87(10):4536–4540. doi:10.1210/jc.2002-020294.
  • Franks S, Gilling-Smith C, Watson H, et al. Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am. 1999;28(2):361–378. doi:10.1016/s0889-8529(05)70074-8.
  • Holte J. Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome. Baillieres Clin Endocrinol Metab. 1996;10(2):221–247. doi:10.1016/s0950-351x(96)80085-1.
  • Crosignani PG, Colombo M, Vegetti W, et al. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod. 2003;18(9):1928–1932. doi:10.1093/humrep/deg367.
  • Sharpe A, Morley LC, Tang T, et al. Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019;12(12):CD013505.
  • Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab. 2013;27(1):13–24. doi:10.1016/j.beem.2012.09.004.
  • Di Carlo C, Gargano V, Sparice S, et al. Effects of an oral contraceptive containing estradiol valerate and dienogest on circulating androgen levels and acne in young patients with PCOS: an observational preliminary study. Gynecol Endocrinol. 2013;29(12):1048–1050. doi:10.3109/09513590.2013.831834.
  • Eslami SS, Gray RH, Apelo R, et al. The reliability of menses to indicate the return of ovulation in breastfeeding women in Manila, the Philippines. Stud Fam Plann. 1990;21(5):243–250. doi:10.2307/1966504.